Skip to main content
Premium Trial:

Request an Annual Quote

Luxembourg Provides $1.3M to WaferGen for European Expansion

NEW YORK (GenomeWeb News) – WaferGen Biosystems has received a €1 million ($1.3 million) matching grant from the Luxembourg government to expand its European operations, the company announced after the close of the market on Tuesday.

The first tranche of €350,000 is expected in the first quarter, the Fremont, Calif.-based company said, and will be used to offset startup and personnel costs. WaferGen is recruiting sales, support, and technical personnel and eventually will establish research and diagnostic capabilities in Luxembourg, where its European operation is headquartered.

In a statement, Ivan Trifunovich, president and CEO of WaferGen, said, "This grant will help us expand our European sales activities and enable us to provide regional support and service capabilities."

WaferGen first announced its plans to establish its European operations in Luxembourg in early 2010. Later that year, the company announced a collaboration with the Integrated BioBank of Luxembourg to co-develop molecular signatures for diagnostic research and commercial applications.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.